BG50273A3 - Method for the preparation of esters of the 1- benzyl- 3- hydroxymethylinedazol - Google Patents

Method for the preparation of esters of the 1- benzyl- 3- hydroxymethylinedazol

Info

Publication number
BG50273A3
BG50273A3 BG091122A BG9112290A BG50273A3 BG 50273 A3 BG50273 A3 BG 50273A3 BG 091122 A BG091122 A BG 091122A BG 9112290 A BG9112290 A BG 9112290A BG 50273 A3 BG50273 A3 BG 50273A3
Authority
BG
Bulgaria
Prior art keywords
benzyl
esters
hydroxymethylinedazol
preparation
general formula
Prior art date
Application number
BG091122A
Other languages
Bulgarian (bg)
English (en)
Inventor
Bruno Silvestrini
Leandro Baiocchi
Original Assignee
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. filed Critical Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Priority to BG093295A priority Critical patent/BG50274A3/xx
Priority to BG093291A priority patent/BG51352A3/bg
Priority to BG093296A priority patent/BG50275A3/xx
Publication of BG50273A3 publication Critical patent/BG50273A3/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
BG091122A 1989-02-07 1990-02-06 Method for the preparation of esters of the 1- benzyl- 3- hydroxymethylinedazol BG50273A3 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
BG093295A BG50274A3 (en) 1989-02-07 1990-02-06 Method for the preparation of esters of 1- benzyl- 3- hydroxymethyl- indazol
BG093291A BG51352A3 (bg) 1989-02-07 1990-02-06 Метод за получаване на етери на 1-бензил-3- хидроксиметил-индазол
BG093296A BG50275A3 (en) 1989-02-07 1990-02-06 Method for the preparation of derivatives of 1- benzyl- indazol- 3- il

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT8947620A IT1230441B (it) 1989-02-07 1989-02-07 Eteri della serie dell'indazolo

Publications (1)

Publication Number Publication Date
BG50273A3 true BG50273A3 (en) 1992-06-15

Family

ID=11261479

Family Applications (1)

Application Number Title Priority Date Filing Date
BG091122A BG50273A3 (en) 1989-02-07 1990-02-06 Method for the preparation of esters of the 1- benzyl- 3- hydroxymethylinedazol

Country Status (36)

Country Link
US (2) US4999367A (enExample)
EP (1) EP0382276B1 (enExample)
JP (1) JP2870925B2 (enExample)
KR (1) KR0145525B1 (enExample)
CN (2) CN1046505C (enExample)
AR (1) AR247386A1 (enExample)
AT (1) ATE127115T1 (enExample)
AU (1) AU624895B2 (enExample)
BG (1) BG50273A3 (enExample)
CA (1) CA2009503C (enExample)
CZ (1) CZ280121B6 (enExample)
DD (2) DD295363A5 (enExample)
DE (2) DE69021902T2 (enExample)
DK (1) DK0382276T3 (enExample)
EG (1) EG19170A (enExample)
ES (1) ES2020171T3 (enExample)
FI (1) FI102678B1 (enExample)
GE (1) GEP19971030B (enExample)
GR (2) GR910300073T1 (enExample)
HU (1) HU204793B (enExample)
IL (1) IL93132A (enExample)
IN (1) IN170957B (enExample)
IT (1) IT1230441B (enExample)
LT (1) LT3604B (enExample)
LV (1) LV10612B (enExample)
NZ (1) NZ232258A (enExample)
PE (1) PE25091A1 (enExample)
PH (1) PH26552A (enExample)
PL (2) PL163720B1 (enExample)
PT (1) PT93067B (enExample)
RO (1) RO106252B1 (enExample)
RU (3) RU2066318C1 (enExample)
SK (1) SK278441B6 (enExample)
UA (1) UA26852C2 (enExample)
YU (1) YU47943B (enExample)
ZA (1) ZA90644B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
US5943270A (en) * 1997-11-26 1999-08-24 Intel Corporation Two-transistor DRAM cell for logic process technology
US7514463B2 (en) * 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
ITMI20062254A1 (it) * 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
EA018185B1 (ru) 2008-03-07 2013-06-28 Ацьенде Кимике Рьюните Анджелини Франческо A.К.P.A.Ф. С.П.А. Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 или cx3cr1
DK2254869T3 (en) 2008-03-07 2017-09-04 Acraf 1-BENZYL-3-HYDROXYMETHYL INDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF CX3CR1 AND P40
MX2010009625A (es) 2008-03-07 2010-09-28 Acraf Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
BR112012002130A2 (pt) * 2009-08-03 2015-09-15 Aziende Chimique Riunite Angelini Francesco A C R A F S P A processo para a preparação de composto,e, composto intermediário
UA108742C2 (uk) * 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
CA3095012C (en) 2012-05-01 2023-02-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
JP2015521183A (ja) 2012-05-18 2015-07-27 サノフイ ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用
DK2882715T3 (en) 2012-05-18 2017-02-13 Sanofi Sa PYRAZOL DERIVATIVES AND USE THEREOF AS LPAR5 ANTAGONISTS
CN108047136B (zh) * 2017-12-20 2021-07-09 长春普华制药股份有限公司 一种苄达酸的精制方法
AU2019441740B2 (en) 2019-04-18 2025-12-18 Tracery Ophthalmics Inc. Detection, prediction, and classification for ocular disease
EP3990433B1 (en) * 2019-06-25 2026-05-20 Translatum Medicus Inc. PROCESSES FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES
CN113929627A (zh) * 2021-10-19 2022-01-14 吕梁学院 一种宾达利的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL28032A (en) * 1966-08-29 1971-08-25 Acraf Indazol-3-yl-oxyalkanoic acids and process for the preparation thereof
US3470298A (en) * 1969-01-29 1969-09-30 Acraf Topical anti-inflammatory composition containing (indazole-3-yl)-oxyalkanoic acids
IT1131779B (it) 1980-07-29 1986-06-25 Acraf Sale dell'acido (1-benzil-1h-indazol-3-il)-ossiacetico con la lisina e procedimento per la sua preparazione
IT1189052B (it) 1981-11-27 1988-01-28 Acraf Trattamento della cataratta
IT1194564B (it) 1983-04-18 1988-09-22 Acraf Impiego del bendazac e dei suoi sali nel trattamento della retinite pigmentosa
IT1197805B (it) 1986-08-01 1988-12-06 Acraf Metodo per il tratamento di lenti a contatto

Also Published As

Publication number Publication date
UA26852C2 (uk) 1999-12-29
RU2044729C1 (ru) 1995-09-27
CA2009503A1 (en) 1990-08-07
CA2009503C (en) 2000-04-11
DE69021902T2 (de) 1996-05-23
ATE127115T1 (de) 1995-09-15
DK0382276T3 (da) 1996-01-15
SK56390A3 (en) 1997-05-07
KR0145525B1 (ko) 1998-08-17
PL163720B1 (pl) 1994-04-29
IL93132A (en) 1994-05-30
SK278441B6 (en) 1997-05-07
AU4906690A (en) 1990-08-16
US5112986A (en) 1992-05-12
EG19170A (en) 1994-11-30
DD295363A5 (de) 1991-10-31
PL163730B1 (pl) 1994-04-29
EP0382276B1 (en) 1995-08-30
ES2020171A4 (es) 1991-08-01
PT93067A (pt) 1990-08-31
DD291995A5 (de) 1991-07-18
HU204793B (en) 1992-02-28
RO106252B1 (ro) 1993-03-31
LT3604B (en) 1995-12-27
PH26552A (en) 1992-08-19
CN1046505C (zh) 1999-11-17
IN170957B (enExample) 1992-06-20
YU47943B (sh) 1996-07-24
CZ280121B6 (cs) 1995-11-15
JP2870925B2 (ja) 1999-03-17
FI900577A0 (fi) 1990-02-06
JPH02240065A (ja) 1990-09-25
RU2066318C1 (ru) 1996-09-10
EP0382276A3 (en) 1990-12-12
US4999367A (en) 1991-03-12
LTIP872A (en) 1995-03-27
DE69021902D1 (de) 1995-10-05
GR910300073T1 (en) 1991-11-15
PE25091A1 (es) 1991-08-17
HUT53088A (en) 1990-09-28
PT93067B (pt) 1995-12-29
YU20690A (sh) 1992-07-20
LV10612A (lv) 1995-04-20
IT1230441B (it) 1991-10-23
CN1088201A (zh) 1994-06-22
FI102678B (fi) 1999-01-29
EP0382276A2 (en) 1990-08-16
CZ56390A3 (en) 1995-06-14
ZA90644B (en) 1991-01-30
RU2055071C1 (ru) 1996-02-27
HU900689D0 (en) 1990-04-28
DE382276T1 (de) 1991-11-28
NZ232258A (en) 1991-06-25
KR900012913A (ko) 1990-09-03
AU624895B2 (en) 1992-06-25
IT8947620A0 (it) 1989-02-07
AR247386A1 (es) 1994-12-29
CN1034016C (zh) 1997-02-12
CN1044810A (zh) 1990-08-22
GR3018165T3 (en) 1996-02-29
IL93132A0 (en) 1990-11-05
ES2020171T3 (es) 1995-12-01
FI102678B1 (fi) 1999-01-29
GEP19971030B (en) 1997-06-13
LV10612B (en) 1995-08-20

Similar Documents

Publication Publication Date Title
AU1813188A (en) Process for the preparation of trialkanolamine di(fatty acid) esters, and the use thereof
RU95112522A (ru) Способ получения клавулановой кислоты, соль клавулановой кислоты и амина
IL132819A0 (en) Use of fumaric acid derivatives
JPS6452716A (en) Endermically applicable preparation containing eperisone, tolperisone or salt thereof
ATE90873T1 (de) Bunazosin oder seine salze enthaltende pharmazeutische zubereitungen zur perkutanen verabreichung.
ES2018479B3 (es) Uso de una sustancia hidrofoba para producir una preparacion enterica para el tratamiento de la obesidad, y una preparacion enterica.
EP0430336A3 (en) Process for the preparation of 4-o-phosphates of dopamine and dopamine derivatives
YU221889A (en) Process for producing new pharmaceutical mixture
AR247386A1 (es) Procedimiento para la preparacion de eteres de 1-bencil-3-hidroximetil-indazol con 2-hidroxiacidos alifaticos y procedimiento para la preparacion de compuesto intermediario utilizado en el mismo
DZ2024A1 (fr) Préparation de sels d'acide clavulanique.
GB1376562A (en) Process for producing citric acid and/or isocitric acid
ES461785A1 (es) Un metodo para la preparacion de un ester de acido behenico.
ZA853830B (en) New cephalosporins and processes for their preparation
ES2071266T3 (es) Procedimiento para la transformacion estereoselectiva de un diol en un alcohol.
DE3776624D1 (de) Verfahren zur herstellung von 2,2-disubstituierten 3-chlorpropionsaeureestern.
GB1514389A (en) Glycerides with antibacterial properties
ES428213A1 (es) Procedimiento para la obtencion de esteres dialquilaminoal-quilicos de penicilina.
JPS6434965A (en) Novel aconitine based compound and analgesic and antiphlogistic agent containing said compound as active ingredient
IL82639A0 (en) Transdermal pharmaceutical composition
ZA9010279B (en) Crystalline magnesium valproate and a method for the preparation thereof
IE870393L (en) Hydroxyindole esters
HUT64291A (en) Method for racemizing non-racemic 3-oxo-cyclopentane-carboxylic acid or 3-oxo-cyclohexanecarboxylic acid, as well as their esters produced with alkohols containing 1 to 6 carbon atoms
ATE77837T1 (de) Verfahren zur herstellung von optisch aktiven bicyclo (3.3.0> octandioncarbonsaeureestern.
TW358029B (en) A pharmaceutical composition containing crystalline chelate of zinc with the extract of bovine prostatic tissue for use in the treatment of diabetes mellitus
ES8301999A1 (es) Procedimiento para la obtencion del ester flalidico del acido 7-d-&-amino-p-hidroxifenilacetamido desacetoxicefalospora-nico y de sus sales.